Cartalax
A Khavinson-family short synthetic peptide positioned as a cartilage bioregulator studied for chondrocyte function and joint tissue support.
Cartalax is a short synthetic peptide from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, developed as a cartilage-targeted 'bioregulator' intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis and connective tissue degeneration. It is most often described as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), though sources report sequence variants. Evidence is predominantly preclinical Russian cell-culture and rodent work plus small uncontrolled observational series; no placebo-controlled human trials exist and it is not approved by any Western regulator.
Class
Synthetic short-peptide bioregulator (Khavinson family)
Half-life
Unknown
Routes
Subcutaneous, Oral, Sublingual
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Chondrocyte function support
Russian in vitro work reports increased chondrocyte activity and matrix production in cartilage cell cultures exposed to Cartalax. The proposed mechanism is preferential activation of chondrogenic transcriptional programmes; evidence is preclinical.
Cartilage matrix synthesis
Cell-culture studies describe increased type II collagen synthesis and aggrecan deposition, markers of extracellular matrix production relevant to cartilage maintenance. This remains at the cell-culture evidence tier.
Anti-catabolic joint effects
In vitro data describe attenuation of IL-1β-induced MMP-13 upregulation, suggesting a proposed anti-catabolic effect that could counter matrix breakdown in osteoarthritis models.
Age-related joint and connective tissue maintenance
As a bioregulator, Cartalax is proposed to modulate gene expression in cartilage-specific cells rather than provide direct structural repair, with research interest in age-related joint degeneration, osteoarthritis, and intervertebral disc degeneration.
Reported symptomatic joint improvement
Small uncontrolled Russian observational series in elderly patients with knee, hip, and spinal osteoarthritis report subjective pain reduction and functional improvement after 20-30 day cycles. These lack placebo control and imaging endpoints.
Mechanism
How it works
Cartalax follows the standard Khavinson short-peptide model applied to cartilage tissue. Being small and polar (reported around 417-445 daltons depending on the sequence variant cited), it is proposed to cross phospholipid bilayers passively, undergo nuclear import, and modulate chromatin in a sequence-selective manner. Khavinson tritiated-peptide biodistribution work describes rapid tissue uptake across cartilage, liver, kidney, and other organs after intraperitoneal or oral administration.
The framework claim is that AEDL reaches chondrocyte nuclei and preferentially upregulates chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs and ADAMTS). Russian in vitro work has reported increased type II collagen and aggrecan deposition and attenuation of IL-1β-induced MMP-13 in chondrocyte cultures, framed as preferential activation of chondrogenic transcription factors and anti-catabolic chromatin states.
A conservative alternative interpretation treats Cartalax simply as a rapidly hydrolysed amino-acid source delivering alanine, glutamate, aspartate, and leucine — with leucine-mediated mTOR activation and substrate delivery potentially explaining any effect. No GPCR, nuclear receptor, or defined enzyme target has been identified, and the tissue-specificity claim is asserted but not confirmed by modern biodistribution, structural biology, or transcriptomic methods. Independent replication outside the Khavinson group is limited.
Within the Khavinson cluster, Cartalax is positioned as the cartilage/connective-tissue counterpart to organ-specific peptides such as Cardiogen (cardiac), Pinealon (brain), and Vesugen (vascular), and as the defined-sequence analogue of cartilage-derived polypeptide extracts (e.g. Sygumir).
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Applies only to synthetic lyophilised AEDL from research-peptide suppliers. Warm the vial to room temperature, clean the stopper, and draw BAC water: a 5 mg vial + 2 mL BAC water yields 2.5 mg/mL. Inject water slowly down the glass side, allow passive dissolution 5-10 minutes, and store at 2-8 C (not frozen). At 2.5 mg/mL, a 2 mg dose = 0.8 mL (80 units U100), 2.5 mg = 1.0 mL, 5 mg = 2.0 mL. Reconstituted peptide is stable roughly 28-30 days; discard if cloudy or with particulate.
Beginner
- Dose
- 1 capsule (20 mg nominal) once daily
- Frequency
- Once daily
- Timing
- Sublingual or oral on an empty stomach, 30-45 min before breakfast; hold sublingual ~60 seconds before swallowing
- Duration
- 10 consecutive days, then stop
- Route
- Oral / sublingual
Use a vendor with third-party HPLC and a certificate of analysis. Minimum 60-day washout before repeating. Track VAS pain, morning stiffness, and range of motion. Continue all existing joint therapy; do not stop NSAIDs or physical therapy to test Cartalax alone.
Intermediate
- Dose
- 20 mg oral daily OR 2-5 mg subcutaneous daily
- Frequency
- Once daily
- Timing
- Oral on empty stomach; SC with site rotation
- Duration
- 10 consecutive days per cycle
- Route
- Oral or subcutaneous
For experienced bioregulator users. Cycle twice yearly (spring and autumn); space at least 2 months from other Khavinson peptides. Commonly stacked with BPC-157 250 mcg SC daily and/or TB-500 2-5 mg weekly for joint-focused work (synergy theoretical). Annual cost roughly 150-300 USD.
Advanced
- Dose
- 20 mg oral/sublingual daily, rotated with other Khavinson peptides
- Frequency
- Once daily during each 10-day block
- Timing
- Empty stomach; annual rotation calendar
- Duration
- 10-day blocks with 2-3 month washouts across a 12-month rotation
- Route
- Oral / sublingual (with optional SC add-ons)
For users with 6+ months Khavinson experience. Example rotation: Month 1 Cartalax 20 mg x10 days; washout; Month 4 Epitalon 5-10 mg SC x10 days; washout; Month 7 Thymogen 100 mcg SC x10 days; washout; Month 10 Cartalax repeat with concurrent BPC-157 250 mcg SC for 30 days. Coordinate with orthopaedics/rheumatology if established OA; baseline and annual imaging plus serial WOMAC/VAS.
- The 20 mg oral capsule contains an undisclosed actual AEDL content (historically estimated 2-4 mg, balance excipients).
- Cycling convention is uniform across Khavinson peptides (10-on / 60-90-off) and has not been empirically optimised for Cartalax specifically.
- No dose-ranging trial has established that 20 mg is optimal. Do not exceed 20 mg oral or 5 mg SC daily; do not run continuous cycles.
- Intraarticular administration is not a Khavinson-convention route and has no published protocol, sterility, or concentration guidance; avoid it. Stick to oral or subcutaneous routes.
- Avoid in severe renal impairment (eGFR <30). Discontinue cycles at least 2 weeks before planned joint surgery.
- Cartalax does not regrow cartilage; the realistic best case is modest symptomatic improvement layered on an evidence-graded foundation of weight management, exercise, and appropriate medical care.
Evidence
Research & clinical studies (4)
KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
In human mesenchymal stem cells the KE (Lys-Glu) peptide increased SIRT1 gene expression and protein synthesis 6- to 8.2-fold in young cells while reducing PARP1/PARP2 expression 2- to 5-fold during aging, with molecular modeling confirming direct DNA binding — providing mechanistic context for geroprotective effects of related cartilage tissue-derived peptides including Cartalax.
PMID 37782636In vitro effects of cartilage bioregulator peptide on chondrocyte cultures (Chalisova et al.)
Russian chondrocyte-culture work reported increased type II collagen synthesis and aggrecan deposition with Cartalax exposure, along with attenuation of IL-1β-induced MMP-13 upregulation.
Khavinson short-peptide tritiated biodistribution study (Khavinson et al.)
Tritiated Khavinson peptide biodistribution work described rapid tissue uptake across cartilage, liver, kidney, and other organs after intraperitoneal or oral administration, though it did not distinguish intact peptide from catabolite signal.
Khavinson-group observational reports in elderly osteoarthritis patients (Khavinson et al.)
Small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis reported subjective pain reduction and functional improvement after 20-30 day cycles, without placebo control or imaging endpoints.
Combinations
Stacking & blends
Joint & Tendon Peptide Stack
Connective tissue and joint recovery support
A common peptide-community pattern that layers Cartalax's proposed cartilage bioregulation on top of BPC-157 (250 mcg SC daily) and TB-500 (2-5 mg weekly), which have more mechanistic and preclinical data for connective tissue regeneration. Interaction safety is considered acceptable; synergy is theoretical.
Khavinson Annual Rotation
Multi-system bioregulator cycling for longevity and joint maintenance
An advanced 12-month rotation that spaces Cartalax (cartilage) cycles from Epitalon (pineal) and Thymogen (immune) blocks by 2-3 month washouts, layered on an evidence-graded joint-care foundation.
Vascular-Connective Tissue Support
Combined connective and vascular tissue bioregulation
Research interest extends to pairing Cartalax with other Khavinson-class peptides such as Cortagen for musculoskeletal and vascular-connective tissue protocols.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy (no reproductive toxicology data)
- Breastfeeding (no excretion/infant safety data)
- Paediatric use
- Active bone/cartilage malignancy or bone metastases
- Severe renal impairment (eGFR <30)
Short-term safety signals from Russian literature and community use are mild, with no serious adverse events reported at convention dosing. However, total documented human exposure is small, modern pharmacovigilance does not exist, and long-term safety over years of cycles is uncharacterised. Use only third-party HPLC-verified product with mass spectrometry identity confirmation, since Cartalax shares amino acid composition with other Khavinson tripeptides. Do not use perioperatively around joint surgery without orthopaedic approval.
FAQ
Cartalax — common questions
What is Cartalax and what is it claimed to do?
Cartalax is a synthetic short peptide (most often described as Ala-Glu-Asp-Leu, AEDL) from Vladimir Khavinson's St. Petersburg Institute, positioned as a cartilage bioregulator for osteoarthritis, intervertebral disc degeneration, and age-related joint decline. Claims include supporting chondrocyte function, matrix synthesis (type II collagen, aggrecan), and anti-catabolic programmes. It is not FDA-approved and appears in no osteoarthritis guideline; treat it as experimental.
Does Cartalax actually help with osteoarthritis?
The evidence is thin. Russian uncontrolled observational series report subjective pain reduction after 20-30 day oral cycles in elderly OA patients, but no placebo-controlled RCTs or imaging-based trial endpoints exist. Evidence-graded first-line care (weight management, structured exercise, NSAIDs, collagen peptides) is far better supported; Cartalax is at best an experimental adjunct.
What is the typical Cartalax dose?
The Khavinson convention is a 20 mg oral or sublingual capsule once daily for 10 consecutive days, with 60-90 day washouts. For reconstituted synthetic peptide, 2-5 mg subcutaneously daily for 10 days is used. Do not exceed 20 mg oral or 5 mg SC daily. Note the 20 mg capsule contains undisclosed actual AEDL content (historically ~2-4 mg).
Is Cartalax safe?
Short-term safety signals are mild — occasional nausea, headache, rare rash, and injection-site reactions — with no serious adverse events reported at convention dosing. But documented human exposure is small and long-term safety is uncharacterised. Absolute contraindications include pregnancy, breastfeeding, paediatric use, and active bone/cartilage malignancy. Use only HPLC-verified product.
Can I stack Cartalax with BPC-157 and TB-500?
Yes — this is a common peptide-community pattern for joint and tendon issues. BPC-157 and TB-500 have more mechanistic data than Cartalax for connective tissue regeneration; combining is considered safe from an interaction standpoint, though synergy is theoretical. Many users prioritise BPC-157/TB-500 and layer Cartalax on as an adjunct.
Can Cartalax be given intraarticularly (into the joint)?
No Khavinson-convention intraarticular protocol exists, and there is no sterility or concentration guidance for this route. Intraarticular injection is a medical procedure appropriate for validated agents (corticosteroids, hyaluronic acid, PRP), not experimental bioregulators. Stick to oral or subcutaneous routes.
How does Cartalax compare to other Khavinson peptides?
Cartalax is the cartilage/connective-tissue member of the Khavinson family, sibling to Pinealon (brain), Thymogen (immune), Cardiogen (cardiac), Vesugen (vascular), and Epitalon (pineal). All share the passive-permeation-plus-chromatin-modulation claim. Cartalax has less published literature than Epitalon or Thymogen and is focused on cartilage indications.
Is Cartalax legal and FDA-approved?
Cartalax is legal to purchase as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption in the US, EU, or most Western markets. No active FDA approval pathway exists as of 2026.
